ArticleCureus2025
Granulometric Analysis After Spontaneous Disintegration of Tablets Containing Micronized Purified Flavonoid Fraction (SIZE Study).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicronized purified flavonoid fraction (MPFF), primarily composed of diosmin and hesperidin, is used to treat chronic venous insufficiency by improving venous function. Traditional diosmin suffers from low bioavailability due to poor solubility, but micronization enhances absorption by reducing particle size. This advancement boosts therapeutic effectiveness, crucial for relieving venous disorder symptoms. Nevertheless, inconsistencies in micronization across manufacturers can affect drug effectiveness, highlighting the need for standardized processes.
objectivesThis study, called the SIZE study, aims to evaluate the particle size distribution of MPFF tablets containing diosmin/hesperidin (900/100 mg) from four Brazilian pharmaceutical manufacturers.
methodsThe spontaneous disintegration method was used to simulate the dissolution process, and granulometric analysis was performed using optical microscopy and image analysis. Samples were collected at 5 and 15 minutes post-disintegration, and particle sizes were categorized into ranges. The spontaneous disintegration method used was not based on the pharmacopoeia, but rather on a study published in 2018.
resultsStatistically significant differences were found between the products, particularly in the 1-5 µm range, with the reference product (Product I) showing the highest percentage of fine particles. This finer granulometry likely contributes to faster dissolution and improved absorption.
conclusionsThe SIZE study highlights the importance of particle size in drug solubility and bioavailability, suggesting that differences in the micronization process affect therapeutic efficacy. The findings underscore the need for standardized regulations on micronization to ensure product consistency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.